New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT03207672
Summary
This is an early-stage safety study testing a new, encapsulated form of a cancer drug called E7389 in people with advanced solid tumors. The main goals are to find the safest highest dose and understand how the body processes the drug. The study will enroll about 140 Japanese adults with various cancers, including breast, lung, and gastric cancers, who have limited treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Eisai Trial Site 1
Chuo-ku, Tokyo, Japan
-
Eisai Trial Site 10
Hidaka, Saitama, Japan
-
Eisai Trial Site 11
Kyoto, Japan
-
Eisai Trial Site 12
Fukuoka, Japan
-
Eisai Trial Site 2
Osaka, Japan
-
Eisai Trial Site 3
Kashiwa, Chiba, Japan
-
Eisai Trial Site 4
Koto-ku, Tokyo, Japan
-
Eisai Trial Site 5
Sapporo, Hokkaido, Japan
-
Eisai Trial Site 6
Yokohama, Kanagawa, Japan
-
Eisai Trial Site 7
Shinjuku-ku, Tokyo, Japan
-
Eisai Trial Site 8
Nishinomiya, Hyōgo, Japan
-
Eisai Trial Site 9
Bunkyo-ku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.